Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Noteable you seem very knowledgeable

<< Previous

Bullboard Posts

Next >>

Comment by Quentin30on Dec 07, 2022 10:38am

89 Views

Post# 35156127

RE:RE:RE:Noteable you seem very knowledgeable

well perhaps you should care about AWARE-1.. our CEO stated back in 2018, that all Roche needed to pull the trigger (on a deal) was AWARE-1 results..

yup, that worked out well.

<< Previous

Bullboard Posts

Next >>

How a junior advances one of the largest undeveloped diamond projects